HatchMed announced that Ernate has been approved for marketing by the Hong Kong Pharmaceutical and Toxicology Committee for the treatment of adult patients with previously treated metastatic colorectal cancer (CRC). Elunate is a selective oral inhibitor of vascular endothelial growth factor (VEGF) receptors -1, -2, and -3, which play a pivotal role in blocking tumor angiogenesis. This is the first drug to be approved under the new mechanism for new drug registration announced by the Hong Kong Special Administrative Region government in October last year. This mechanism was officially launched on November 1, 2023. Under this mechanism, medicines that are beneficial in the treatment of life-threatening or severely debilitating diseases can be applied for registration for use in Hong Kong, provided there is supporting local clinical data and approval from relevant experts. Allowed. They are only approved by one reference drug regulatory authority. HatchMed submitted the application based on Elunate's approval from China's National Pharmaceutical Administration (NMPA), which was supported by local clinical data. Fruquintinib was also approved by the FDA in November 2023.
It was first published fly – The ultimate source of real-time financial news that moves the markets. Try it now >>
See today's best performing stocks on TipRanks >>
Read more about HCM:
